Mean (± S.E.) change from baseline in the 6-min walk distance for bosentan (n = 21) and placebo (n = 11) groups. Mean (± S.E.) change from baseline in.

Slides:

Advertisements

Similar presentations

Bosentan for inoperable chronic thromboembolic pulmonary hypertension (CTEPH) and post- pulmonary endarterectomy pulmonary hypertension A pre-defined subgroup.

Advertisements

Volume 357, Issue 9273, Pages (June 2001)

RESULTS OF THE RIMONABANT IN OBESITY (RIO) PROGRAM AT 1 YEAR

Representative 10-s EEG recordings from GAERS: during baseline (prior to injection of any drug) (i), following the i.c.v. injection of 4 μl of vehicle.

Placebo Metformin ***p < vs placebo

Monthly improvements in paid work productivity: ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) subpopulations (employed.

Monthly improvements in family, social and leisure activities to week 96 (last observation carried forward imputation). Assessed using the arthritis-specific.

Monthly improvements in paid work productivity: overall axial spondyloarthritis population (employed patients only; last observation carried forward imputation). Assessed.

Figure 2 Cumulative proportion of patients experiencing a seizure recurrence after randomization, comparing immediate vs deferred treatment Cumulative.

James H. Liu, MD The American Journal of Medicine

Volume 70, Issue 8, Pages (October 2006)

Volume 92, Issue 1, Pages 2-3 (July 2017)

Comparison of the model incorporating daily dose to that incorporating Cmax. Comparison of the model incorporating daily dose to that incorporating Cmax.

The context-sensitive half-times for commonly used intravenous anesthetic drugs. [Reproduced from Reves JG, Glass PSA, Lubarsky DA, McEvoy MD, and Martinez-Ruiz.

Total ion current-EMS chromatograms of SB939 and its metabolites after incubation in liver microsomal fractions for 60 min at a concentration of 50 μM.

Osteoarthritis year 2010 in review: pharmacological therapies

Has the 6-Min Walk Distance Run Its Course?

Nat. Rev. Cardiol. doi: /nrcardio

Structure of solid lipid nanoparticles (SLNs).

Phylogenetic tree of the human class Frizzled receptors FZD1–10 and SMO created with the ClustalW2 software (ver ;

The three primary ADC components that determine which cells are targeted (antibody), how the drug is released (linker/trigger), and the mechanism of action.

Pulmonary Hypertension after Hematopoietic Stem Cell Transplantation

The effect of sequential addition of sildenafil to first-line epoprostenol on exercise capacity measured using 6-min walk distance (6MWD) in the PACES.

Mechanisms of H2S release from S-aroylthiooximes (SATOs).

Cytotoxic activities of polymer micelles containing CFZ in H460 (A) and select micelle formulations in RPMI-8226 (B) cell lines. Cytotoxic activities of.

Cytotoxic effects of PM1 and PM2 empty particle controls and coincubation of CFZ with empty particles tested in H460 (A) and RPMI-8226 (B) cells. Cytotoxic.

Geometric mean concentration-time profiles of (A) racemic BUP, R-BUP, and S-BUP; (B) racemic OHBUP, RR-OHBUP, and SS-OHBUP; (C) racemic ERY, SR-ERYHBUP,

The additive model assumes unspecific effects of equal size in both the placebo and drug arm or groups of studies or experiments. The additive model assumes.

Key pathways involved in the pathogenesis of pulmonary arterial hypertension: a) endothelin (ET) pathway; b) nitric oxide pathway; and c) prostacyclin.

Challenges and Opportunities in Hormone-Resistant Prostate Cancer

Level of physical activity by Global Initiative for Obstructive Lung Disease (GOLD) stage, BODE (body mass index, FEV1 for airflow obstruction, dyspnoea,

Clinical and patient-reported outcomes for patients randomised to CZP 200 mg Q2W and CZP 400 mg Q4W to week 96. Clinical and patient-reported outcomes.

Lukas Hinterhuber, Ivo W. Graziadei, Christian M

Risk assessment and treat-to-target approach for pulmonary arterial hypertension. Risk assessment and treat-to-target approach for pulmonary arterial hypertension.

Comparison of the observed and calculated CLR values of taurine and GCDCA-S. Comparison of the observed and calculated CLR values of taurine and GCDCA-S.

(A) Illustration depicting two types of pharmacokinetic instability of an ADC. Conjugating an antibody with drug can accelerate its clearance (green versus.

The changing distribution of endothelin (ET)A and ETB subtypes with decreasing vessel diameter. a) ET-1 binding and b) distribution of ETA and ETB receptors.

Mean change from baseline in 6-min walking distance (6MWD) in the Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase–Stimulator Trial.

(A) Absolute and (B) change from baseline in 6 min walk distance over time for all patients and by Down syndrome status. (A) Absolute and (B) change from.

Change in 6 min walk distance from baseline to each follow-up time for subjects randomised to CABG and to medical therapy alone. The median change and.

Copyright © 2013 Elsevier Inc. All rights reserved.

Change in forced vital capacity (FVC) % predicted (% pred) per week from baseline in the CAPACITY 004 and 006 study comparing pirfenidone (2403 mg·day−1)

Mean change from baseline in 6MWD in (A) Chinese patients with PAH in PATENT-1 and (B) Chinese patients with CTEPH in CHEST-1. Mean change from baseline.

Effects of gemfibrozil on the exposure (area under the plasma drug concentration-time curve) to different CYP2C8 substrate drugs. Effects of gemfibrozil.

(A) Absolute and B) change from baseline in 6 min walk distance over time for patients on bosentan monotherapy by Down syndrome status. (A) Absolute and.

Proportion of patients in each World Health Organization functional class (WHO-FC) at the time of pulmonary arterial hypertension-associated systemic sclerosis.

The first Bedside Assessment, Stabilisation and Initial Cardiorespiratory Support (BASICS) prototype (by PW in April 2011, reprinted with his permission).

Results of thermogravimetric measurements of peptide ghrelin antagonist (GhA) and loaded into PSi microparticles. Results of thermogravimetric measurements.

Pulmonary arterial hypertension specific medication use at enrolment among previously diagnosed patients. 184 (7%) of patients were not on a prostaglandin,

Results of classification and regression tree analysis in patients with pulmonary hypertension-sickle cell disease. Results of classification and regression.

The effect of inhaled tiotropium (18 μg once daily) on the improvement in treadmill exercise endurance time in patients with chronic obstructive pulmonary.

Survival of idiopathic pulmonary arterial hypertension (IPAH) patients in World Health Organization functional class (FC) at baseline IV is extremely poor.

Fraction of dose (mean, n = 3–4) recovered in peripheral lymph following subcutaneous administration to sheep for a series of small molecular compounds.

Stereoimage of three independent docking simulations of the interaction between clopidogrel acyl 1-β-d-glucuronide and the active site of CYP2C8. Stereoimage.

Monthly improvements in home productivity: ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) subpopulations (last observation.

Damage-associated molecular pattern (DAMP)-induced activation of Toll-like receptors (TLRs). Damage-associated molecular pattern (DAMP)-induced activation.

Changes in glycated hemoglobin (HbA1c) levels after 12 weeks’ treatment with lixisenatide (according to dose increase regimen) or placebo. Changes in glycated.

CBD elevates AEA levels in poly-(I:C)–stimulated HaCaT cells after 6 hours. CBD elevates AEA levels in poly-(I:C)–stimulated HaCaT cells after 6 hours.

Apparent diffusion coefficient versus the degree of DWMI in NPH and age-matched controls, showing significantly higher ADC (indicating higher water content)

The CYP2C8 gene is located to the CYP2C gene cluster on chromosome 10.

Kaplan-Meier curves for overall survival in patients with adenocarcinoma and time since first-line therapy of

Progression in the patient’s pulmonary function tests from 2010 to a) Forced vital capacity (FVC); b) total lung capacity (TLC); c) diffusing capacity.

Effect of pulmonary arterial hypertension-specific treatment on systemic inflammation. a) Kaplan–Meyer survival curves for patients normalising their C-reactive.

Activation and desensitization of the α7 nAChRs.

Effects of placebo or carvedilol CR on 24-hour mean systolic blood pressure and diastolic blood pressure obtained by ambulatory monitoring in hypertensive.

Reduction in mean pulmonary vascular resistance (PVR) in 37 subjects following acute sildenafil administration to ongoing bosentan therapy in the COMPASS-1.

Neighbor joining tree showing relationships between the human cannabinoid CB1 and CB2 receptors and other human rhodopsin α-group type G protein-coupled.

Vasopressin stimulation of V2 and V1a receptors can contribute to events that worsen cardiac function. [Reprinted from J Am Coll Cardiol, vol. 47, Schrier.

Baseline New York Heart Association functional class (NYHA FC) predicts survival in patients with pulmonary hypertension using infused epoprostenol therapy.

Effect of placebo (n=88) and bosentan (n=80) on the co-primary end-point pulmonary vascular resistance (PVR) in the EARLY (Endothelial Antagonist Trial.

Presentation transcript:

Mean (± S.E.) change from baseline in the 6-min walk distance for bosentan (n = 21) and placebo (n = 11) groups. Mean (± S.E.) change from baseline in the 6-min walk distance for bosentan (n = 21) and placebo (n = 11) groups. Patients who did not complete week 20 assessments (bosentan, n = 1; placebo, n = 4) had their last observed values carried forward. *, P < 0.05 versus baseline, P = 0.021 versus placebo at week 12. [Reprinted from Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, et al. (2001) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet358:1119–1123. Copyright © 2001 Elsevier, Inc. Used with permission.] Lyn R. Frumkin Pharmacol Rev 2012;64:583-620 © 2012 by The American Society for Pharmacology and Experimental Therapeutics